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Abstract
Background Currently, acellular dermal substitutes used
for skin reconstruction are usually covered with split-
thickness skin grafts. The goal of this study was to develop
an animal model in which such dermal substitutes can be
tested under standardized conditions using a bioengineered
dermo-epidermal skin graft for coverage.
Methods Bioengineered grafts consisting of collagen type
I hydrogels with incorporated human fibroblasts and human
keratinocytes seeded on these gels were produced. Two
different dermal substitutes, namely Matriderm, and an
acellular collagen type I hydrogel, were applied onto full-
thickness skin wounds created on the back of immuno-
incompetent rats. As control, no dermal substitute was
used. As coverage for the dermal substitutes either the
bioengineered grafts were used, or, as controls, human
split-thickness skin or neonatal rat epidermis were used.
Grafts were excised 21 days post-transplantation. Histol-
ogy and immunofluorescence was performed to investigate
survival, epidermis formation, and vascularization of the
grafts.
Results The bioengineered grafts survived on all tested
dermal substitutes. Epidermis formation and vasculariza-
tion were comparable to the controls.
Conclusion We could successfully use human bioengi-
neered grafts to test different dermal substitutes. This novel
model can be used to investigate newly designed dermal
substitutes in detail and in a standardized way.
Keywords Dermal substitutes  Matriderm 
Tissue engineering  Split-thickness skin  Dermis 
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Introduction
The today’s gold standard to treat full-skin defects such as
burns, giant nevi, or avulsion injuries is the transplantation
of autologous split-thickness skin [1, 2]. Split-thickness
skin can be applied directly on the wound bed, or it can be
transplanted onto different acellular dermal substitutes
such as Integra (Integra) [1, 3–7] or Matriderm (Matri-
derm) [8–13]. Dermal substitutes improve wound healing,
impede scar contraction and the cosmetic outcome com-
pared to transplanted split-thickness skin alone [1, 14, 15].
A newly designed dermal substitute needs to be tested pre-
clinically for its biological behavior and compatibility with
split-thickness skin. For most dermal substitutes, tests are
performed in a pig animal model with porcine split-thick-
ness skin [16–19].
The aim of this experimental study was to test whe-
ther a human bioengineered skin graft can be used to
replace human split-thickness skin for the pre-clinical
testing of acellular dermal substitutes used for skin
reconstruction.
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Materials and methods
Cell isolation and culture
Human skin samples were obtained after informed consent
from patients and/or parents; all described studies were
approved by the Medical Ethical Committee of the Kanton
Zurich. Human primary fibroblasts and keratinocytes were
isolated as previously described [20].
Engineered dermal substitutes (acellular collagen
hydrogels)
To engineer acellular dermal substitutes, a solution of
bovine collagen type I was neutralized with a NaOH con-
taining buffer [21] and poured into cell culture inserts with
a pore size of 3 lm (BD Falcon, Basel, Switzerland). After
incubation for 2 h at 37 C, the acellular dermal substitutes
were plastically compressed as previously described [22].
The acellular collagen hydrogels were incubated for 5 days
in Rheinwald and Green medium (RGM) [20], before
transplantation, with medium changes performed every
2–3 days.
Matriderm
Matriderm 1 mm (Dr. Suwelack Skin and Health Care AG,
Billerbeck, Germany) was cut into round pieces of 26 mm
diameter and incubated in RGM for 3 min immediately
before transplantation.
Human bioengineered skin grafts (bioengineered grafts)
Human bioengineered skin grafts based on collagen type I
hydrogels with incorporated human dermal fibroblasts and
human keratinocytes seeded on these hydrogels were cre-
ated as previously described [23]. Briefly, 105 human pri-
mary dermal fibroblasts were mixed with bovine collagen
type I (BD Biosciences, Basel, Switzerland) and neutral-
ized with a buffer containing NaOH. The solution was
poured into cell culture inserts with a pore size of 3 lm
(BD Falcon, Basel, Switzerland). After incubation of 2 h at
37 C and 5 % CO2, the hydrogels were plastically com-
pressed [22]. The hydrogels were cultivated in DMEM
supplemented with 10 % FCS, and media changes were
performed every 2–3 days. 7.5 9 105 human primary
keratinocytes were seeded onto the complete surface of the
hydrogels 5 days thereafter. After 3 days of submerged
cultivation in RGM, hydrogels were cultivated for addi-
tional 3 days at the air–liquid interface, before transplan-
tation onto immuno-incompetent rats.
Human split-thickness skin
Human split-thickness skin (leftovers from split-thickness
skin transplantations) was received from patients from the
University Children’s Hospital Zurich after informed con-
sent from patients and/or parents. Split-thickness skin was
stored in DMEM at 4 C until transplantation.
Neonatal rat epidermis
Neonatal rat epidermis of appropriate size was obtained
from full-thickness skin samples from newborn Wistar rats
(University of Zurich animal breeding program). Full-
thickness skin samples were treated overnight in dispase
(BD Biosciences) diluted 1:1 in Hank’s balanced salt
solution (Invitrogen) containing 5 mg/ml gentamicin
(Invitrogen) at 4 C. To obtain an epidermis free of dermal
components, the epidermis was peeled off the dermis
immediately before transplantation.
Transplantation
All animal experiments were approved by the local Com-
mittee for Experimental Animal Research. The preparation
of immuno-incompetent nu/nu rats (age 8–10 weeks, Har-
lan, Horst, The Netherlands) was performed as previously
described [24]. Steel rings with a diameter for 26 mm were
implanted into full-thickness skin defects on the back of the
rats to prevent wound closure by ingrowth of rat skin into
the wound area. Two different dermal substitutes, namely
Matriderm and engineered acellular collagen hydrogels,
were placed onto the wounds. The dermal substitutes were
immediately covered with (a) human bioengineered graft,
(b) human split-thickness skin, or, (c) neonatal rat epider-
mis. Controls were performed without any dermal sub-
stitute, where the coverage grafts were transplanted directly
on the fascia (Fig. 1). Transplants were covered with a
silicon foil (Silon-SES, BMS, Allentown, PA, USA).
Sample sizes for each group are summarized in Table 1.
Once a week, wound dressing changes and photographic
documentations were performed. Animals were sacrificed
21 days post-transplantation. Grafts were excised, halved,
and embedded in O.C.T compound (Tissue-Tek, Sakura
Finetek, Japan) or fixed in 4 % paraformaldehyde (Medite
Medizintechnik AG, Nunningen, Switzerland) and then
embedded in paraffin (McCormick, Richmond, USA).
Histology
For hematoxylin and eosin staining, 10 lm thick paraffin
sections were cut and stainings were imaged by light
microscopy [Nikon Eclipse TE2000-U inverted microscope
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connected with a DXM1200F digital camera (Nikon AG,
Egg, Switzerland)].
For immunofluorescence stainings, O.C.T embedded
tissue was frozen at -20 C, and sectioned at 10 lm.
Permeabilization was performed in ice-cold acetone for
5 min, thereafter sections were air-dried, and washed three
times in phosphate buffered saline (PBS). After blocking
with PBS containing 2 % bovine serum albumin (Sigma,
Buchs, Switzerland) for 30 min at room temperature, sec-
tions were incubated with the pre-labeled antibodies for 1 h
at room temperature. Sections were washed three times
with PBS, then nuclei were stained with 1 lg/ml Hoechst
33341 (Sigma, Buchs, Switzerland) in PBS for 5 min at
room temperature. Sections were washed two times with
PBS, and finally mounted with Dako fluorescent mounting
solution (Dako, Baar, Switzerland).
Antibodies
The following antibodies were used: K1 (clone LHK1,
1:200, Novus Biologicals, Littleton, USA); Lam5a3 (clone
P3H9-2, 1:100, Santa Cruz, Labforce AG, Nunningen,
Switzerland); CD31 (clone TDL-3A12, 1:50, BD Biosci-
ences Pharmingen, Basel, Switzerland); CD90 (clone AS02,
1:100, Dianova, Hamburg, Germany).
Fig. 1 Schematic overview on the different combinations of dermal
substitutes and coverage used in this study. Human bioengineered
graft transplanted onto the fascia (a), on Matriderm (b), or, on
engineered acellular collagen hydrogel (c). Human split-thickness
skin transplanted onto the fascia (d), on Matriderm (e), or, on
engineered acellular collagen hydrogel (f). Neonatal rat epidermis
transplanted onto the fascia (g), on Matriderm (h), or, on engineered
acellular collagen hydrogel (i)
Table 1 Summary of the sample sizes for each group
On
fascia
On
Matriderm
On acellular
collagen
Human bioengineered graft 10 3 4
Human split-thickness skin 1 1 1
Neonatal rat epidermis 4 4 4
Pediatr Surg Int (2013) 29:479–488 481
123
For immunofluorescence stainings, primary antibodies
were pre-labeled with either Alexa488 or Alexa555 con-
jugated polyclonal goat F(ab0)2 fragments, according to the
manufacturer’s instructions (Zenon Mouse IgG Labelling
Kit, Molecular Probes, Invitrogen, Basel, Switzerland).
Fluorescence microscopy
The immunofluorescence stainings were analyzed with a
Nikon Eclipse TE2000-U inverted microscope, equipped
with Hoechst, FITC and TRITC filter sets and connected
with a DXM1200F digital camera (Nikon AG, Egg,
Switzerland).
Results
Macroscopic appearance of epidermis on transplanted
grafts
Immediately after transplantation, the human bioengi-
neered grafts macroscopically appeared similar in all
groups (transplanted either directly on the fascia, on Ma-
triderm, or, on an engineered acellular collagen hydrogel)
(Fig. 2a–c). At the time point of transplantation, human
split-thickness skin macroscopically looked similar in all
three groups, the underlying dermal substitute was not
visible through the split-thickness skin (Fig. 2d–f). At the
Fig. 2 Macroscopic view of grafts at the time point of transplanta-
tion. a–c Human bioengineered graft appearance is similar in all three
groups. The underlying engineered acellular collagen hydrogel is
detectable in c (arrow). d–f Human split-thickness skin shows similar
appearance in all three groups. g–h Neonatal rat epidermis looks
similar when transplanted onto fascia and Matriderm. i Neonatal rat
epidermis looks pale when transplanted onto engineered acellular
collagen hydrogels. Diameter of the ring (arrow in a) 26 mm (a–i)
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time point of transplantation, neonatal rat epidermis
appeared very thin and transparent (Fig. 2g–i) and the
underlying dermal substitute was visible. Matriderm
seemed red and dull, as a result from its incubation in RGM
prior to transplantation (Fig. 2h). The engineered acellular
collagen hydrogel shined white through the neonatal rat
epidermis (Fig. 2i).
21 days post-transplantation, a complete take of the
bioengineered grafts in all three groups was observed
(Fig. 3a–c). Grafts showed an epithelialized surface and
seemed well integrated into the rat tissue. 21 days post-
transplantation, the split-thickness skins seemed well
integrated into the rat tissue and in all three groups good
take was observed with epidermis covering the complete
surface (Fig. 3d–f). 21 days post-transplantation, neonatal
rat epidermis transplanted directly onto the fascia (Fig. 3g)
macroscopically showed a better take rate compared to
neonatal rat epidermis transplanted on Matriderm (Fig. 3h)
and on engineered acellular collagen gel (Fig. 3i).
Histological analysis of grafts excised 21 days post
transplantation
Grafts excised 21 days post-transplantation were sectioned
and stained with hematoxylin and eosin. Human bioengi-
neered grafts showed a stratified epidermis of 6–9 layers
Fig. 3 Macroscopic view of grafts 21 days post-transplantation.
a–c Human bioengineered grafts show complete take in all three
groups. Grafts look almost identical in all three groups. d–f Human
split-thickness skin shows complete take in all three groups. Grafts
look almost identical in all three groups. g–i Neonatal rat epidermis
shows only partial take that is similar in all three groups. The
surviving epidermal islets look very fragile and do not seem to be
firmly attached to the wound bed
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that was similar in all three groups (Fig. 4a–c). Remnants
of Matriderm could be detected between the bioengineered
graft and the underlying rat tissue (Fig. 4b). The bioengi-
neered graft could be distinguished from the engineered
acellular collagen hydrogel, which was partially populated
by rat cells (Fig. 4c).
Human split-thickness skin showed similar appearance in
all three groups, with a multi-layered epidermis, prominent
rete ridges, and a very prominent stratum corneum (Fig. 4d–f).
Transplantation of neonatal rat epidermis was partially
successful when transplanted directly on the fascia, where a
2–3 layered epidermis could be detected (Fig. 4g). When
transplanted on Matriderm (Fig. 4h) or on engineered
acellular collagen gel (Fig. 4i), the epidermis did not sur-
vive, and only some single epidermal cells could be
detected. The Matriderm material could not be clearly
distinguished from the underlying rat tissue (Fig. 4h). The
engineered acellular collagen hydrogel was clearly
Fig. 4 Histological evaluation of grafts (hematoxylin and eosin
staining) excised 21 days post-transplantation. a Human bioengi-
neered grafts transplanted onto the fascia show 6–9 keratinocyte
layers and the dermal part of the bioengineered graft can be clearly
distinguished from the underlying tissue (cg collagen gel). b Human
bioengineered grafts transplanted on Matriderm show similar appear-
ance as in a. Remnants of Matriderm are detectable between the
bioengineered graft and the underlying rat tissue (M Matriderm).
c Human bioengineered grafts transplanted on acellular collagen
show similar appearance as in a. The border between graft and
engineered acellular collagen hydrogel can be discerned (dotted line).
d–f Human split-thickness skin looks similar in all three groups. The
normally configured epidermis shows a stratum corneum (arrows)
and rete ridges (arrow heads). g Neonatal rat epidermis transplanted
onto the fascia is very thin and unstratified (black line). h Neonatal rat
epidermis transplanted onto Matriderm does not survive, no epidermis
is detectable. i Neonatal rat epidermis transplanted on engineered
acellular collagen hydrogel does not survive, only single epidermal
cells are occasionally detectable. The collagen gel is easily discern-
able and there are almost no cells. (acg engineered acellular collagen
hydrogel). Scale bars 100 lm (a–i)
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detectable and was only partially colonized by ingrown rat
cells (Fig. 4i).
Basal lamina deposition and epidermis stratification
Grafts excised 21 days post-transplantation were sectioned
and immunofluorescence stainings were performed. Stain-
ing with an antibody to the basal lamina component lam-
inin 5 revealed the deposition of a continuous basal lamina
in human bioengineered grafts in all three groups (Fig. 5a–
c). In bioengineered grafts, all suprabasal keratinocyte
layers expressed keratin 1 (Fig. 5a–c). Similar expression
patterns for laminin 5 and keratin 1 were observed in
transplanted human split-thickness skin in all three groups
(Fig. 5d–f). In the specimens where neonatal rat epidermis
was transplanted, neither basal lamina deposition nor ker-
atin 1 expression was detected in either group (Fig. 5g–i).
In human bioengineered grafts, the ingrowth of rat blood
vessels, as detected by staining with CD31, was similar in
all three groups (Fig. 6a–c). The human fibroblasts of the
bioengineered graft could be detected by staining with
CD90 in all groups (Fig. 6a–c). Similarly, in specimens
covered with human split-thickness skin, rat blood vessels
were found in proximity to the epidermis (Fig. 6d–f). The
human origin was confirmed by CD90 staining, which was
expressed by human fibroblasts in the split-thickness skin
(Fig. 6d–f). In specimens covered with neonatal rat epi-
dermis, the ingrowth of rat blood vessels was similar in all
three groups (Fig. 6g–i). No human fibroblasts expressing
CD90 were detected (Fig. 6d–i).
Fig. 5 Immunofluorescence stainings (laminin 5 and keratin 1) of
grafts excised 21 days post-transplantation. a–c In human bioengi-
neered grafts in all three groups, staining of the basement membrane
component laminin 5 (red) reveals the deposition of a continuous
basement membrane. In all three groups, all suprabasal cells express
keratin 1 (green). d–f Human split-thickness skin in all three groups
shows similar expression of laminin 5 (red) and keratin 1 (green) as
described for a–c. g–i In all three groups with neonatal rat epidermis
transplantation, there is no laminin 5 (red) nor keratin 1 (green)
expression. Scale bars 50 lm
Pediatr Surg Int (2013) 29:479–488 485
123
Discussion
The goal of this experimental study was to test whether a
human bioengineered skin graft can be used to replace
human split-thickness skin for the pre-clinical testing of
acellular dermal substitutes used for skin reconstruction.
These bioengineered grafts were compared to the cur-
rent standard coverage of dermal substitutes, i.e. split-
thickness skin, and to neonatal rat epidermis. In the global
picture, human bioengineered grafts demonstrated a very
similar biological behavior as split-thickness skin, while
neonatal rat epidermis performed significantly poorer.
Several points deserve a detailed comment: Split-
thickness skin was used as positive control for the new
model, as split-thickness skin transplantation is the gold
standard for complex dermo-epidermal skin reconstruction
in clinical practice since more than 10 years [1, 25, 26].
Interestingly, we found that the human bioengineered graft
behaved as well as split-thickness skin. When transplanted
on Matriderm as well as on engineered acellular collagen
hydrogel, the bioengineered skin grafts show similar bio-
logical performance as seen with transplantation of split-
thickness skin. A continuous basal lamina was deposited as
evidenced by staining for the basal lamina component
laminin 5, and all suprabasal cells expressed keratin 1 as is
seen in normal homeostatic skin. Rat blood vessels grew
into the dermal part of the bioengineered grafts and so
ensured sufficient oxygen and nutrient supply for the
Fig. 6 Immunofluorescence stainings (CD31 and CD90) of grafts
excised 21 days post-transplantation. a–c In human bioengineered
grafts in all three groups, staining with CD31 (red) reveals the
ingrowth of rat blood vessels into the dermal part of the coverage
graft. Also, human fibroblasts expressing CD90 (green) are detected
in all groups. d–f In human split-thickness skin, rat blood vessels
grew into the dermal part as detected by CD31 staining (red). Human
fibroblasts are detected by staining with CD90 (green). g–i In
neonatal rat epidermis in all three groups, staining with CD31 (red)
reveals the ingrowth of rat blood vessels into the transplants. In all
three groups, no human fibroblasts expressing CD90 (green) are
detected. Scale bars 50 lm
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epidermis. The presence of human fibroblasts, which are
indispensable key players regarding skin architecture and
functionality, in the bioengineered skin grafts could be
confirmed by the detection of human CD90-specific cells.
In sharp contrast, the performance of neonatal rat epi-
dermis alone was significantly poorer. The most tenable
explanation for the good performance of the bioengineered
graft and split-thickness skin as opposed to rat epidermis is
the presence of dermal components in the former and a
complete lack of those elements in the latter. It is well
documented in the literature that viable and functional
dermal elements are crucial for epidermal viability and
functionality [27–31].
The almost identical biological behavior of the bioen-
gineered grafts compared to split-thickness skin indicates
that human bioengineered grafts might be used in the future
instead of split-thickness skin as standard dermo-epidermal
coverage to test any newly designed dermal substitutes. Of
note, human bioengineered grafts can be prepared in a very
standardized way in terms of cell numbers, cell types, and
thickness of the graft. The use of a humanized model
represents an additional advantage, given the fact that the
mentioned preclinical testing procedures may lead to
applications in human patients.
In summary and conclusion, this series of experiments
provides evidence that human bioengineered skin grafts
can successfully be employed to test different acellular
dermal substitutes designed for skin reconstruction. Such
testing is indispensable before new products can be applied
clinically.
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